Previous 10 | Next 10 |
NEW YORK and BASEL, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at the following investor conference...
Gainers: Tile Shop Holdings (NASDAQ: TTS ) +53% . Cemtrex (NASDAQ: CETX ) +40% . PB Bancorp (NASDAQ: PBBI ) +30% . Sunworks (NASDAQ: SUNW ) +24% . The Dixie Group (NASDAQ: DXYN ) +24% . Nautilus (NYSE: NLS ) +22% . Nano Dimension (NASDAQ: NNDM ) +22% . Trans World Entertainmen...
Thinly traded micro cap Axovant Gene Therapies (NASDAQ: AXGT ) is up 15% premarket on light volume in reaction to preliminary data from an expanded access study administering gene therapy candidate AXO-AAV-GM2 to two patients with Tay-Sachs disease , a rare inherited neurodege...
Initial data with AXO-AAV-GM2 suggests stabilization of disease course, attainment of normal developmental milestones, and improvement in myelination on brain MRI AXO-AAV-GM2 generally safe and well-tolerated to date Additional data to be presented by Dr. Terence Flotte at 5:30 PM ...
NEW YORK and BASEL, Switzerland, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD, AXO-AAV-GM...
Noteworthy events during the week of September 29 - October 5 for healthcare investors. More news on: Capricor Therapeutics, Inc., Enanta Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Healthcare stocks news, , Read more ...
BASEL, Switzerland, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag Meswani, Pharm.D., senior vice president, commercial strategy & operations, will present at the an...
Axovant Gene Therapies ( AXGT ) is running three clinical programs on three gene therapy candidates for neurological and developmental disorders. Readouts from all three programs are expected in Q4'19, presenting an opportunity for a trade, which is the focus of this article. A big Q4'19 u...
Investment thesis Interpreting low-dose Cohort 1 data as functionally active strengthens Phase 1b results and bodes well for Phase 2 data. The premise of this investment thesis is that a low-dose placebo effect for a gene-therapy asset held by Voyager Therapeutics (VYGR), a biotech com...
Mitsubishi Tanabe Pharma America ( OTCPK:MTZPY -1.5% ) initiates a Phase 3 clinical trial, BouNDless , evaluating continuous subcutaneously administered carbidopa/levodopa (ND0612) compared to the oral formulation in Parkinson's disease (PD) patients. More news on: Mitsubishi Tanabe P...
News, Short Squeeze, Breakout and More Instantly...
Axovant Gene Therapies Ltd. Company Name:
AXGT Stock Symbol:
NYSE Market:
On-track to report t opline r esults from low-dose cohort by end of 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to ra...
A pioneering researcher , Dr. Gao has made foundational contributions to the discovery of novel AAV vectors for gene therapy Dr. Gao recently served as President of the American Society for Gene and Cell Therapy (ASGCT) and has been ranked as one of...
Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020 ...